Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 2
R&D Momentum
59/100
Pipeline Velocity
6/100
Trial Completion Rate
81/100
Pipeline Concentration
50/100
Pipeline Freshness
21/100
Strategic Signals
Activity
Last 14 days
Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan
Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban
Bariatric Surgery and Pharmacokinetics Hydrochlorothiazide: BAR-MEDS Hydrochlorothiazide
Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin
The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease - The Link Between DISC1 and Cardiac Function in Patients With Schizophrenia
Bariatric Surgery and Pharmacokinetics of Ramipril: BAR-MEDS Ramipril
The Norwegian Exercise in Atrial Fibrillation Trial - An Open-label, Multicenter Randomized Controlled Trial Comparing an eHealth-based Exercise Intervention With Usual Care After 12 Months Follow-up
Bariatric Surgery and Pharmacokinetics Quetiapine: BAR-MEDS Quetiapine
Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril
Bariatric Surgery and Pharmacokinetics of Chlorprothixene: BAR-MEDS Chlorprothixene
Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)